briacell therapeutics corp immunotherapy approaches to cancer management briacell is a los angeles headquartered biotechnology company focused on immunotherapy treatments for cancer management. to date, the company has been successful in developing its patented "briavax" vaccine and implementing two compelling fda phase-i studies with late-stage breast cancer patients, demonstrating unique and unprecedented results. briacell is focused on aggressively moving towards launching its next clinical trial, a phase-i/ii study, in order to apply its vaccine to a larger number of breast cancer patients and effectively progress its technology along the value chain. while the current corporate focus is breast cancer, the company has an eye towards potentially applying its vaccine technology to certain other cancer types as well.
Company profile
Ticker
BCTX
Exchange
Website
CEO
William V. Williams
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Ansell Capital Corp.
SEC CIK
BCTX stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
18 Mar 24
EFFECT
Notice of effectiveness
1 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
31 Jan 24
CORRESP
Correspondence with SEC
29 Jan 24
UPLOAD
Letter from SEC
29 Jan 24
S-3
Shelf registration
22 Jan 24
DEF 14A
Definitive proxy
9 Jan 24
8-K
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
20 Dec 23
10-Q
2024 Q1
Quarterly report
14 Dec 23
8-K
Condesed Interim Financial Statements
14 Dec 23
Latest ownership filings
SC 13G/A
Lynwood Capital Management Inc.
14 Feb 23
4
Jamieson Bondarenko
28 Dec 22
4
William V. Williams
28 Dec 22
4
Jamieson Bondarenko
20 Dec 22
3
Jamieson Bondarenko
11 Aug 22
3
Marc Lustig
2 Aug 22
3
Priore Giuseppe Del
1 Aug 22
3
Rebecca Taub
1 Aug 22
3
Miguel A. Lopez-Lago
1 Aug 22
3
Martin E. Schmieg
1 Aug 22
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jul 23 | Jul 22 | Jul 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.65 mm | 13.65 mm | 13.65 mm | 13.65 mm | 13.65 mm | 13.65 mm |
Cash burn (monthly) | 2.54 mm | 1.98 mm | 2.83 mm | 2.20 mm | 2.54 mm | 2.32 mm |
Cash used (since last report) | 12.55 mm | 9.82 mm | 14.03 mm | 10.88 mm | 12.55 mm | 11.47 mm |
Cash remaining | 1.10 mm | 3.82 mm | -385.55 k | 2.77 mm | 1.10 mm | 2.17 mm |
Runway (months of cash) | 0.4 | 1.9 | -0.1 | 1.3 | 0.4 | 0.9 |
Institutional ownership, Q2 2023
45.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 9 |
Closed positions | 5 |
Increased positions | 6 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 19.11 bn |
Total shares | 7.32 mm |
Total puts | 1.15 k |
Total calls | 137.60 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Lynwood Capital Management | 1.58 mm | $10.17 bn |
L5 Capital | 1.53 mm | $10.28 mm |
Southwest Private Capital | 782.01 k | $6.73 mm |
AULT Ault Alliance | 715.00 k | $5.41 mm |
Wasatch Advisors | 612.09 k | $3.93 bn |
CVI Investments | 600.00 k | $0.00 |
Armistice Capital | 375.00 k | $937.50 mm |
Redmond Asset Management | 212.69 k | $1.07 bn |
Bigger Capital Fund L P | 150.00 k | $1.24 mm |
L1 Capital Global Opportunities Master Fund | 105.00 k | $869.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Dec 22 | Jamieson Bondarenko | Common Shares | Buy | Acquire P | No | No | 4.58 | 28,000 | 128.24 k | 169,856 |
23 Dec 22 | Williams V. Williams | Warrant Common Shares | Buy | Acquire P | No | No | 1.94 | 2,530 | 4.91 k | 29,802 |
20 Dec 22 | Jamieson Bondarenko | Common Shares | Buy | Acquire P | No | No | 5.35 | 22,000 | 117.70 k | 141,856 |
News
BriaCell Receives And Executes Letter Of Intent To Advance Clinical Development Of Breast And Prostate Cancer Immunotherapies
7 Mar 24
BriaCell Provides Update On Alleged Illegal Trading Of Public Securities
27 Feb 24
BriaCell Reports Prelim Disease Control Rate Of 61% In Evaluable Phase 2 Advanced Breast Cancer Patients Treated With Briacell's Bria-imt Regimen; Control Rate Of 50% Reported In Evaluable Patients Who Failed Prior ADC Therapy
7 Feb 24
BriaCell Images Confirm Robust Anti-Tumor Activity In Patient With "Eye-Bulging" Metastatic Breast Cancer
4 Jan 24
Press releases
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
6 Mar 24
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
7 Feb 24
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
6 Feb 24
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
30 Jan 24
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer
4 Jan 24